Site Map     Privacy & Terms

dermaPACE™ Studied in Chronic Wounds

The dermaPACE™ device has been shown to significantly decrease the size of diabetic foot ulcers in a recent multi-center, randomized, sham-controlled, pivotal Phase III clinical trial when used in conjunction with standard dressings.

Read more about the dermaPACE™ clinical trial

Learn more about dermaPACE™
News

Jan 6, 2011 - SANUWAVE Health Submits to FDA Second Module of PMA Application for dermaPACEā„¢ for the Treatment of Diabetic Foot Ulcers

Dec 15, 2010 - SANUWAVE Health Announces Positive Top-Line Data from its Pivotal Trial Investigating the Use of dermaPACE™ for the Treatment of Diabetic Foot Ulcers

Dec 10, 2010 - SANUWAVE Health Submits to FDA First Module of PMA Application for dermaPACE™ for the Treatment of Diabetic Foot Ulcers
About SANUWAVE

A pioneer in the field of regenerative medicine, SANUWAVE specializes in the development and commercialization of
non-invasive, biological response activating devices based on the PACE™ Technology platform.

Learn more about ESWT and PACE™ Technology

PACE™ Technology


Copyright © 2006-2010 SANUWAVE Health, Inc. All Rights Reserved. OssaTron, EvoTron, VersaTron, dermaPACE, OrthoTripsy and “Healing Today. Curing Tomorrow.” are all registered trademarks of SANUWAVE.